Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Sep 8, 2026, 12:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Intervention: Victoza® Clear all

Conditions: Obesity
Interventions: Saxenda®, Placebo; Drug · Other
Lead sponsor: Texas Tech University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Lubbock, Texas

Conditions: Obesity
Interventions: Weight Management Program (WMP), Medication for chronic weight management (Rx); Other · Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: liraglutide, alpha-glucosidase inhibitors, DPP-4 inhibitors, meglitinides, SGLT-2 inhibitors, sulphonylurea, thiazolidinediones; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,991 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 179
States / cities: Birmingham, Alabama • Haleyville, Alabama • Tuscumbia, Alabama + 157 more

Conditions: Obesity
Interventions: AMG 598, Placebo, Liraglutide; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Birmingham, Alabama • Tustin, California • South Miami, Florida + 1 more

Conditions: Type 2 Diabetes Mellitus
Interventions: 50 mg PB1023, 70 mg PB1023, 100 mg PB1023, Placebo (0.9% Sodium Chloride), Victoza®, Diet and Exercise, Metformin, Sulfonylurea, Metformin and Sulfonylurea; Drug · Other
Lead sponsor: PhaseBio Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 593 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 93
States / cities: Anniston, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 90 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin glargine, Liraglutide, Metformin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 35 Years to 75 Years
Enrollment: 978 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 45
States / cities: Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 39 more

Conditions: Type 2 Diabetes (T2DM)
Interventions: SGLT-2 inhibitor, GLP1-RA; Drug
Lead sponsor: MaryAnn Banerji; Other
Eligibility: 24 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin degludec, insulin aspart, liraglutide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 48
States / cities: Concord, California • La Jolla, California • Lancaster, California + 44 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin degludec/liraglutide, liraglutide, exenatide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 438 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 85
States / cities: Birmingham, Alabama • Goodyear, Arizona • Mesa, Arizona + 73 more

Conditions: Metabolism and Nutrition Disorder, Obesity
Interventions: liraglutide, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 422 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 27
States / cities: Goodyear, Arizona • Peoria, Arizona • Huntington Beach, California + 22 more

Conditions: Bipolar Disorder, Obesity
Interventions: LIRAGLUTIDE, Placebo; Drug · Other
Lead sponsor: Lindner Center of HOPE; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Mason, Ohio

Conditions: Type 2 Diabetes
Interventions: Liraglutide + OADs, Glargine + OADs; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 5
States / cities: Miami, Florida • Atlanta, Georgia • New York, New York

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: liraglutide, glimepiride, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 746 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 102
States / cities: Concord, California • Escondido, California • Fullerton, California + 83 more

Conditions: Pre-Diabetes
Interventions: Liraglutide, Weight loss; Drug · Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 4
States / cities: Los Angeles, California • Torrance, California • Houston, Texas

Conditions: Overweight, Obesity
Interventions: NNC0174-0833, Placebo (NNC0174-0833), Liraglutide 3.0 mg, Placebo (Liraglutide 3.0 mg); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 706 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 22
States / cities: Anaheim, California • Spring Valley, California • Crystal River, Florida + 19 more

Search by objective public record fields.

To Predict Weight Loss Response to Liraglutide (Saxenda®), From fMRI-based Determination of Food Cue Reactivity

Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity

Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes

Multiple Ascending Dose Study of AMG 598 in Adults With Obesity

Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM

Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure

Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists

Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy

Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance

Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)

Liraglutide Hospital Discharge Trial

To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c

Improving Beta Cell Function in Mexican American Women With Prediabetes

Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.